Home > Boards > US OTC > Medical - Equipment > Lexington Biosciences Inc. (LXGTF)

A couple of weeks ago I posted about

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
77Port Member Profile
 
Followed By 3
Posts 301
Boards Moderated 0
Alias Born 08/27/18
160x600 placeholder
77Port   Tuesday, 08/27/19 04:11:39 PM
Re: None
Post # of 12411 
A couple of weeks ago I posted about Abbatis, a crooked Canadian cannabis company which was being delisted due to being part of the crooked consulting firm, the Vancouver based Bridgemark Group. It included multiple, cross-referenced pump/dump schemes.
https://highenergytrading.com/cse-scam-allert-this-is-what-happens-when-you-do-sketchy-things-with-sketchy-companies/?fbclid=IwAR15zamoCiEC8gem80SxjwE1_vOmnmBuOirfr0VF7Q3oxY8Uy0CJ0xq00Eg

While neither cannabis nor crypto, in 2017, LEX got their hand slapped by the same watchdog:
https://highenergytrading.com/13-cannabis-crypto-companies-caught-otc/

At the time, if you look back on our posts, many of us towed the line about how this couldn't possibly be real. Later, LEX was able to clear themselves, partially by this release:
https://www.pressreader.com/
Search Lexington Biosciences and you can find this article here, which is attempting to get out from under the POS Renmark financial group which LEX allowed to manage their PR. Perhaps LEX never recovered from this blight on their reputation? Or maybe they were able to cover the sham? We really don't know.

TEXT from above article:
Quote:
Lexington warns investors about Techstock materials
Lexington Biosciences Inc. is warning investors about promotional materials published by Techstock Insider, paid for apparently by Ellis Stewart LLC. The materials inaccurately state the company’s HeartSentry product as being biometric and wearable.
Stockwatch Daily3 Nov 2017Mr. Eric Willis reports

LEXINGTON BIOSCIENCES Inc. is issuing this press release at the request of the OTC Markets Group Inc.

On Oct. 17, 2017, the company’s management became aware of certain promotional materials that were published by Techstock Insider that were purportedly paid for by Ellis Stewart LLC. The company wishes to advise investors that they should only rely on information provided to the market by the company and does not support or endorse the information in the mate- rials published on this website. For information about the company, investors should go to the company’s website or review the company’s public disclosure record available at SEDAR. Lexington did not pay for or review the materials published by Techstock Insider and does not have any relationship with Ellis Stewart. The company notes that the materials are inaccurate in a number of places, including describing the company’s principal product, HeartSentry, as “biometric” and “wearable.” HeartSentry is best described as a “cardiovascular diagnostic medical device.”

The company has engaged the following groups to provide investor relations and marketing services: Renmark Financial Communications Inc., Hybrid Financial Ltd. and Audience Marketing.

The company further notes that none of the company’s management, directors or third party service providers have sold any shares of the company in the last 90 days.

At the request of OTC Markets Group, the company confirms that in the last 12 months, it has issued the following securities at the following prices: (a) 6.25 million units (consisting of a share plus one-half warrant) at 20 cents per unit; and (b) 2.53 million units (consisting of a share plus a whole warrant) at 25 cents per unit.

About Lexington Biosciences Inc.

Lexington Biosciences is a medical device company developing the HeartSentry, a new non-invasive diagnostic device to measure and moni- tor cardiovascular health by assessing the function of a person’s vascular endothelium — the vital innermost lining of a person’s cardiovascular system. Currently, the standard of care is measurement using expensive external ultrasound by a highly trained technician. The HeartSentry core technology was developed at the University of California Berkeley over a 15-year research and development period involving many research studies and product iterations resulting in portfolio of multiple pending and issued patents licensed to the company. By taking delivery of the clinical trial-ready HeartSentry units, the company will commence studies as soon as possible.

We seek Safe Harbor.

Bryan Disher, Douglas Glen Janzen, Rocco Rossi, Eric Willis

(LNB) Shares: 30,745,901



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist